Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

  1. Karolina Partheen1,†,*,
  2. Kristina Levan1,
  3. Lovisa Österberg1,
  4. Ingela Claesson1,
  5. Ghita Fallenius1,
  6. Karin Sundfeldt2,
  7. György Horvath1

Article first published online: 15 AUG 2008

DOI: 10.1002/ijc.23758

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 9, pages 2130–2137, 1 November 2008

Additional Information

How to Cite

Partheen, K., Levan, K., Österberg, L., Claesson, I., Fallenius, G., Sundfeldt, K. and Horvath, G. (2008), Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. International Journal of Cancer, 123: 2130–2137. doi: 10.1002/ijc.23758

Author Information

  1. 1

    Department of Oncology, University of Gothenburg, Gothenburg, Sweden

  2. 2

    Department of Obstetrics and Gynecology, University of Gothenburg, Gothenburg, Sweden

  1. †

    Fax: +46-31-41-72-05.

*Department of Oncology, University of Gothenburg, SE-413 45 Gothenburg, Sweden

Publication History

  1. Issue published online: 25 AUG 2008
  2. Article first published online: 15 AUG 2008
  3. Manuscript Accepted: 20 MAY 2008
  4. Manuscript Received: 28 MAR 2008

Funded by

  • King Gustav V Jubilee Clinic Cancer Research Foundation
  • The Assar Gabrielsson Foundation
  • The Swedish Cancer Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (369K)

Keywords:

  • ovarian cancer;
  • biomarkers;
  • clusterin;
  • integrin beta 3;
  • preferentially expressed antigen in melanoma;
  • capping protein (actin filament) gelsolin-like

Abstract

The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein expressions for 7 potential biomarkers, to determine if it is possible to use them as prognostic factors. Genes selected from our previous microarray analysis (2006), CLU, ITGB3, TACC1, MUC5B, CAPG, PRAME and TROAP, were analyzed in 19 of the tumors with quantitative real-time polymerase chain reaction (QPCR). We found that CLU and ITGB3 were more expressed in tumors from survivors and PRAME and CAPG were more expressed in tumors from deceased patients. None of the other 3 genes were significantly differently expressed. The protein expressions of CLU, ITGB3, PRAME and CAPG were analyzed in 43 of the tumors with western blot for semiquantitative analysis. We established that the mRNA and protein expressions correlated and that all 4 proteins were significantly differently expressed. Further, immunohistochemistry (IHC) was used to localize the expression of the proteins in the tumor samples. According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas. © 2008 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (369K)